Novartis says Avidity's science could apply beyond muscular dystrophies

Novartis said it's working to get the most out of its $12 billion acquisition of Avidity Biosciences by finding ways to apply its underlying science to diseases beyond muscular dystrophy. The drugmaker’s 2025